Search company, investor...
nextbio company logo


Founded Year



Acquired | Acquired

Total Raised


About nextbio

NextBio is a life sciences data search engine that introduces the web 2.0 paradigm of instant access and search, user-generated content and collaboration to life scientists and clinicians. NextBio empowers users to formulate and test new hypotheses across vast collections of experimental data in a simple way. With a powerful data search engine that goes far beyond the limits of published literature and traditional text mining, NextBio is bringing the wealth of large-scale life sciences information to your fingertips. The widespread use of high throughput technologies in academic and commercial organizations across all stages of basic and clinical research has created a need to effectively store, manage and search massive volumes of information. NextBio provides a unified interface for researchers to take advantage of data from internal and public studies and quickly transform it into knowledge and discoveries.

Headquarters Location

475 El Camino Real Suite 100

Santa Clara, California, 95050,

United States


Missing: nextbio's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: nextbio's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

nextbio Patents

nextbio has filed 8 patents.

patents chart

Application Date

Grant Date


Related Topics




Data types, Knowledge representation, Data management, Natural language processing, Abstract data types


Application Date


Grant Date



Related Topics

Data types, Knowledge representation, Data management, Natural language processing, Abstract data types



Latest nextbio News

Cypher Genomics, Illumina partner to facilitate development of genomic-based biomarkers

Jul 24, 2014

Published on July 24, 2014 at 7:26 AM· No Comments Cypher Genomics , Inc., the genome informatics company, announced today a co-promotion agreement with Illumina to facilitate the development of genomic-based biomarkers from whole genome sequence data for precision medicine and clinical trials. Cypher Genomics and Illumina will jointly offer pharmaceutical companies, through Illumina's sales force, a solution including Illumina's market leading sequencing technology, the NextBio platform for data analytics and storage, and Cypher Genomics' biomarker discovery service, called CoralTM. Cypher Genomics technology reduces the signal-to-noise in genomic information to uncover important biomarkers in sample sizes typical of early stage drug development studies. "Cypher Genomics' biomarker discovery service is a perfect complement to Illumina's whole genome sequencing and our NextBio analytics platform," said Nick Naclerio, SVP Corporate Development and General Manager Enterprise Informatics of Illumina. "We look forward to working with Cypher Genomics to provide our mutual customers with the sequencing, data interpretation, and data mining they require for biomarker discovery with whole genome data. " Related Stories Fabry disease awareness: an interview with Dr. Hartmann Wellhoefer, Head of Medical Affairs, Rare Disease, Shire "We founded Cypher Genomics to transform the practice of medicine through fast and accurate genome interpretation. Cypher Genomics' biomarker discovery service, Coral™, includes technology that has a proven track record of success with pharmaceutical companies to discover the genetic basis of response to drug therapy," states Ashley Van Zeeland, Ph.D., co-founder and chief executive officer of Cypher Genomics. The benefits of biomarker discovery to deliver precision medicine is clear – better tools that can match therapies to patients not only improves clinical outcomes but also reduce clinical trial sizes, which can accelerate time to market for life-saving therapies. Many desire to look beyond biomarker panels to the whole genome, but biomarker discovery based on whole genome data generally has not been feasible due to the lack of statistical power within the small sample sizes of early clinical studies. Cypher's genomic analysis platform provides highly accurate genome annotations combined with advanced statistical techniques to enable biomarker discovery studies with sample sizes in the hundreds, reflecting the reality of many Phase 2 clinical trials. Adam Simpson, president and chief operating officer of Cypher Genomics, added, "Working with Illumina to offer best-in-class sequencing and analysis to pharmaceutical companies enables acceleration of their personalized drug development efforts and will ultimately help deliver on the promise of precision medicine. " Source:

nextbio Frequently Asked Questions (FAQ)

  • When was nextbio founded?

    nextbio was founded in 2004.

  • Where is nextbio's headquarters?

    nextbio's headquarters is located at 475 El Camino Real, Santa Clara.

  • What is nextbio's latest funding round?

    nextbio's latest funding round is Acquired.

  • How much did nextbio raise?

    nextbio raised a total of $15M.

  • Who are the investors of nextbio?

    Investors of nextbio include Illumina, Newbury Ventures and Amidzad Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.